Overview

A Study on the Safety and Effectiveness of Rilpivirine Hydrochloride (Edurant) Among Adult Filipino Patients With Human Immunodeficiency Virus Type-I Infection

Status:
Withdrawn
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and effectiveness of rilpivirine hydrochloride in combination with other anti-retroviral (ARV) medications for the treatment of ARV-naive (patients who have not been exposed to ARV) Filipino patients with human immunodeficiency virus type 1 (HIV-1) infection.
Details
Lead Sponsor:
Janssen Pharmaceutica
Treatments:
Rilpivirine